公开(公告)号：US20230365582A1

公开(公告)日：2023-11-16

申请号：US18042352

申请日：2021-08-20

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Young Sook SHIN ,  Sang Kyun LIM ,  Yeri LEE ,  Donggeon KIM ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyun Jin KIM ,  Joo Youn LEE ,  Hyuk LEE ,  Sikwang SEONG

IPC: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

CPC classification number: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.

公开(公告)号：US20230248734A1

公开(公告)日：2023-08-10

申请号：US18001333

申请日：2021-06-08

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Soo Bong HAN ,  Jin Soo SHIN ,  Mee Hyein KIM ,  Eunhye JUNG ,  Ye Jin JANG ,  Hyuk LEE ,  Myoungkyu LEE ,  Dongsu KIM ,  Chang Soo YUN ,  Young Sik JUNG

IPC: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/50

CPC classification number: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/5091

Abstract: The present invention relates to the development of a composition for the treatment of novel SARS-coronavirus-2 infection. The drug efficacy was evaluated through CPE (Cytopathic Effect)-based assay method that measures how long the cells survive by infecting SARS-CoV-2 after receiving a drug library previously approved as a treatment for a specific disease from the Korea Chemical Bank and treating Vero cells with the drug, and an image-based assay that measures how much virus is reduced in infected cells. Through this, 16 kinds of drugs effective in the treatment of SARS-CoV-2 were re-positioned.

公开(公告)号：US20210047300A1

公开(公告)日：2021-02-18

申请号：US16967825

申请日：2019-01-31

Applicant: Korea Research Institute of Chemical Technology ,  Industry-Academic Cooperation Foundation, Yonsei University

Inventor： Sung Youn CHANG ,  Hyuk LEE ,  Ki Young KIM ,  Bum Tae KIM ,  Sung Soo KIM ,  Seong Hwan KIM ,  Hwan Jung LIM ,  Jung Nyoung HEO ,  Sang Joon SHIN ,  Sang Youn PARK

IPC: C07D403/12 ,  C07D413/14 ,  C07D401/12 ,  C07D403/14 ,  C07D413/12 ,  C07D417/14

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

公开(公告)号：US20210047277A1

公开(公告)日：2021-02-18

申请号：US16967844

申请日：2019-01-31

Applicant: Korea Research Institute of Chemical Technology ,  Industry-Academic Cooperation Foundation, Yonsei University

Inventor： Sung Youn CHANG ,  Hyuk LEE ,  Ki Young KIM ,  Bum Tae KIM ,  Sung Soo KIM ,  Seong Hwan KIM ,  Hwan Jung LIM ,  Jung Nyoung HEO ,  Sang Joon SHIN ,  Sang Youn PARK

IPC: C07D231/38 ,  C07D403/10 ,  C07D401/04 ,  C07D409/04 ,  C07D417/04 ,  C07D401/14 ,  A61P35/04

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

公开(公告)号：US20250161271A1

公开(公告)日：2025-05-22

申请号：US18838591

申请日：2023-02-15

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Donggeon KIM ,  Yeri LEE ,  Sang Kyun LIM ,  Young Sook SHIN ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyuk LEE ,  Hyun Jin KIM ,  Joo Youn LEE ,  Si Kwang SEONG ,  Taeyoung YOON ,  Youngrae LEE

IPC: A61K31/407 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4155 ,  A61K31/4436 ,  A61K31/4535 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and/or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.

公开(公告)号：US20230039679A1

公开(公告)日：2023-02-09

申请号：US17939147

申请日：2022-09-07

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Sung Youn CHANG ,  Hyuk LEE ,  Ki Young KIM ,  Bum Tae KIM ,  Sung Soo KIM ,  Seong Hwan KIM ,  Hwan Jung LIM ,  Jung Nyoung HEO ,  Sang Joon SHIN ,  Sang Youn PARK

IPC: C07D231/38 ,  A61P35/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/10 ,  C07D409/04 ,  C07D417/04

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.